Which has better earnings & valuation, CRSP or ALMS?

Alumis has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CRISPR Therapeutics $3.51M 1,558.06 -$581.60M -$4.76 N/A Alumis $7.40M 135.94 -$243.32M -$3.86 N/A

Is CRSP or ALMS more profitable?

CRISPR Therapeutics has a net margin of -3,368.72% compared to Alumis' net margin of -5,933.46%. CRISPR Therapeutics' return on equity of -24.39% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics -3,368.72% -24.39% -18.25% Alumis -5,933.46% -93.15% -74.50%

Does the media prefer CRSP or ALMS?

In the previous week, CRISPR Therapeutics had 9 more articles in the media than Alumis. MarketBeat recorded 15 mentions for CRISPR Therapeutics and 6 mentions for Alumis. CRISPR Therapeutics' average media sentiment score of 0.65 beat Alumis' score of 0.41 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 6 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ACAD or ALMS?

In the previous week, Alumis had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 6 mentions for Alumis and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.71 beat Alumis' score of 0.41 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EWTX or ALMS?

In the previous week, Alumis had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 6 mentions for Alumis and 5 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.59 beat Alumis' score of 0.41 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ALMS or PBLS?

Parabilis Medicines has lower revenue, but higher earnings than Alumis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alumis $7.40M 135.94 -$243.32M -$3.86 N/A Parabilis Medicines N/A N/A N/A N/A N/A

Does the media favor ALMS or PBLS?

In the previous week, Alumis and Alumis both had 6 articles in the media. Parabilis Medicines' average media sentiment score of 0.56 beat Alumis' score of 0.41 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Parabilis Medicines 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, CELC or ALMS?

Celcuity has higher earnings, but lower revenue than Alumis. Celcuity is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Alumis $7.40M 135.94 -$243.32M -$3.86 N/A

Is CELC or ALMS more profitable?

Celcuity has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Alumis -5,933.46% -93.15% -74.50%

Does the media prefer CELC or ALMS?

In the previous week, Alumis had 1 more articles in the media than Celcuity. MarketBeat recorded 6 mentions for Alumis and 5 mentions for Celcuity. Celcuity's average media sentiment score of 0.69 beat Alumis' score of 0.41 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alumis (ALMS) Competitors

$7.77 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.94 +0.18 (+2.25%)

As of 05:50 AM Eastern

Compare

ALMS vs. CRSP, ACAD, EWTX, PBLS, and CELC

Should you buy Alumis stock or one of its competitors? Alumis's main competitors and comparable companies include CRISPR Therapeutics (CRSP), ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), Parabilis Medicines (PBLS), and Celcuity (CELC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alumis compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, CRISPR Therapeutics had 9 more articles in the media than Alumis. MarketBeat recorded 15 mentions for CRISPR Therapeutics and 6 mentions for Alumis. CRISPR Therapeutics' average media sentiment score of 0.65 beat Alumis' score of 0.41 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	6 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Alumis has a beta of -0.81, suggesting that its stock price is 181% less volatile than the broader market.

CRISPR Therapeutics has a net margin of -3,368.72% compared to Alumis' net margin of -5,933.46%. CRISPR Therapeutics' return on equity of -24.39% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Alumis	-5,933.46%	-93.15%	-74.50%

Alumis has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,558.06	-$581.60M	-$4.76	N/A
Alumis	$7.40M	135.94	-$243.32M	-$3.86	N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 33.7% of Alumis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CRISPR Therapeutics presently has a consensus price target of $67.94, indicating a potential upside of 20.12%. Alumis has a consensus price target of $33.27, indicating a potential upside of 328.22%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.59
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

CRISPR Therapeutics and Alumis tied by winning 8 of the 16 factors compared between the two stocks.

How does Alumis compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

ACADIA Pharmaceuticals has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.07B	4.39	$391M	$2.22	12.29
Alumis	$7.40M	135.94	-$243.32M	-$3.86	N/A

In the previous week, Alumis had 3 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 6 mentions for Alumis and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.71 beat Alumis' score of 0.41 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Alumis' net margin of -5,933.46%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%
Alumis	-5,933.46%	-93.15%	-74.50%

ACADIA Pharmaceuticals presently has a consensus price target of $34.36, suggesting a potential upside of 25.91%. Alumis has a consensus price target of $33.27, suggesting a potential upside of 328.22%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Alumis has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats Alumis on 11 of the 17 factors compared between the two stocks.

How does Alumis compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Edgewise Therapeutics has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Alumis has a beta of -0.81, suggesting that its share price is 181% less volatile than the broader market.

Edgewise Therapeutics has higher earnings, but lower revenue than Alumis. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Alumis	$7.40M	135.94	-$243.32M	-$3.86	N/A

In the previous week, Alumis had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 6 mentions for Alumis and 5 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.59 beat Alumis' score of 0.41 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Edgewise Therapeutics' return on equity of -39.01% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Alumis	-5,933.46%	-93.15%	-74.50%

Edgewise Therapeutics currently has a consensus price target of $50.33, indicating a potential upside of 11.06%. Alumis has a consensus price target of $33.27, indicating a potential upside of 328.22%. Given Alumis' stronger consensus rating and higher probable upside, analysts plainly believe Alumis is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Edgewise Therapeutics beats Alumis on 7 of the 13 factors compared between the two stocks.

How does Alumis compare to Parabilis Medicines?

Alumis (NASDAQ:ALMS) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Alumis currently has a consensus target price of $33.27, indicating a potential upside of 328.22%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential downside of 0.15%. Given Alumis' stronger consensus rating and higher possible upside, equities analysts plainly believe Alumis is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Alumis and Alumis both had 6 articles in the media. Parabilis Medicines' average media sentiment score of 0.56 beat Alumis' score of 0.41 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Parabilis Medicines	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines has lower revenue, but higher earnings than Alumis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$7.40M	135.94	-$243.32M	-$3.86	N/A
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A

Parabilis Medicines has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Parabilis Medicines' return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Parabilis Medicines	N/A	N/A	N/A

Summary

Alumis and Parabilis Medicines tied by winning 4 of the 8 factors compared between the two stocks.

How does Alumis compare to Celcuity?

Celcuity (NASDAQ:CELC) and Alumis (NASDAQ:ALMS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Celcuity has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Alumis has a beta of -0.81, indicating that its stock price is 181% less volatile than the broader market.

In the previous week, Alumis had 1 more articles in the media than Celcuity. MarketBeat recorded 6 mentions for Alumis and 5 mentions for Celcuity. Celcuity's average media sentiment score of 0.69 beat Alumis' score of 0.41 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celcuity has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Alumis	-5,933.46%	-93.15%	-74.50%

63.3% of Celcuity shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 33.7% of Alumis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Celcuity presently has a consensus price target of $154.75, indicating a potential upside of 91.97%. Alumis has a consensus price target of $33.27, indicating a potential upside of 328.22%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Celcuity has higher earnings, but lower revenue than Alumis. Celcuity is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Alumis	$7.40M	135.94	-$243.32M	-$3.86	N/A

Summary

Alumis beats Celcuity on 9 of the 16 factors compared between the two stocks.

Get Alumis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALMS vs. The Competition

Export

Metric	Alumis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$3.89B	$7.22B	$12.94B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-2.01	14.23	275.48	25.40
Price / Sales	135.94	1,451.66	653.49	82.06
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	2.70	15.65	10.57	6.32
Net Income	-$243.32M	-$22.90M	$3.49B	$358.20M
7 Day Performance	-15.73%	-1.33%	-0.23%	0.42%
1 Month Performance	-67.85%	-4.51%	-2.67%	-3.30%
1 Year Performance	86.33%	37.80%	18.17%	5.33%

Alumis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALMS Alumis	3.9486 of 5 stars	$7.77 flat	$33.27 +328.2%	+86.3%	$1.01B	$7.40M	N/A	239
CRSP CRISPR Therapeutics	2.4134 of 5 stars	$51.72 -1.0%	$68.06 +31.6%	-9.2%	$5.05B	$3.51M	N/A	393
ACAD ACADIA Pharmaceuticals	4.4025 of 5 stars	$27.83 +0.3%	$34.36 +23.5%	+11.8%	$4.78B	$1.07B	12.54	798	Positive News
EWTX Edgewise Therapeutics	2.4227 of 5 stars	$44.40 +3.5%	$50.33 +13.4%	+217.8%	$4.66B	N/A	N/A	127	Positive News Options Volume
PBLS Parabilis Medicines	1.5696 of 5 stars	$36.88 +1.5%	$41.67 +13.0%	N/A	$4.49B	N/A	N/A	145	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALMS) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alumis (ALMS) Competitors

ALMS vs. CRSP, ACAD, EWTX, PBLS, and CELC

How does Alumis compare to CRISPR Therapeutics?

Summary

How does Alumis compare to ACADIA Pharmaceuticals?

Summary

How does Alumis compare to Edgewise Therapeutics?

Summary

How does Alumis compare to Parabilis Medicines?

Summary

How does Alumis compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alumis (ALMS) Competitors

ALMS vs. CRSP, ACAD, EWTX, PBLS, and CELC

How does Alumis compare to CRISPR Therapeutics?

Does the media prefer CRSP or ALMS?

Which has more volatility & risk, CRSP or ALMS?

Is CRSP or ALMS more profitable?

Which has better earnings & valuation, CRSP or ALMS?

Do insiders and institutionals believe in CRSP or ALMS?

Do analysts rate CRSP or ALMS?

Summary

How does Alumis compare to ACADIA Pharmaceuticals?

Which has preferable earnings & valuation, ACAD or ALMS?

Does the media prefer ACAD or ALMS?

Is ACAD or ALMS more profitable?

Do analysts rate ACAD or ALMS?

Do insiders & institutionals hold more shares of ACAD or ALMS?

Which has more volatility and risk, ACAD or ALMS?

Summary

How does Alumis compare to Edgewise Therapeutics?

Which has more volatility & risk, EWTX or ALMS?

Which has better valuation and earnings, EWTX or ALMS?

Does the media favor EWTX or ALMS?

Is EWTX or ALMS more profitable?

Do analysts rate EWTX or ALMS?

Summary

How does Alumis compare to Parabilis Medicines?

Do analysts recommend ALMS or PBLS?

Does the media favor ALMS or PBLS?

Which has stronger earnings & valuation, ALMS or PBLS?

Is ALMS or PBLS more profitable?

Summary

How does Alumis compare to Celcuity?

Which has more volatility & risk, CELC or ALMS?

Does the media prefer CELC or ALMS?

Is CELC or ALMS more profitable?

Do insiders and institutionals believe in CELC or ALMS?

Do analysts recommend CELC or ALMS?

Which has better valuation & earnings, CELC or ALMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS vs. The Competition

Alumis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools